Before a preclinical pain experiment is begun, significant consideration
should be given to the model organism, pain assay, holding and testing
environments, and number and type of behavioural measures. Increased variability
in model organism species, genetic background, age, sex and life history may
increase the translatability of preclinical findings. To determine the
generalizability of a new pain target or mechanism, experimenters should use
multiple clinically relevant assays within a given study instead of a single,
artificial injury. Specific care should be taken to minimize environmental
stress before and during pain behaviour testing; appropriate habituation times
are absolutely necessary to mitigate the effects of stress-induced analgesia or
hyperalgesia on behavioural responses. Lastly, the number, type, and resolution
of measures should be increased to allow more nuanced interpretations of pain
behaviours during both the acute phase and the chronic phase of the injury.